SARS-CoV-2 Pocketome: Severe Acute Respiratory Syndrome Coronavirus 2, Pockets Identification for Antiviral & Antimicrobial Phytomolecules and Drug Repurposing

23 June 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

According to WHO, the current Coronavirus disease situation is 8,506,107 confirmed and 455,231 death cases in approx 216 Countries, areas, or territories. For the treatment of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) drug repurposing seems to be an effective strategy as it could shorten the time and reduce the cost compared to de novo drug discovery. For that, we need to identify target binding sites. Thus, we have reported for the first time structural druggability assessment for SARS-CoV-2 proteome a pan-druggability prediction based on the open-source pocket detection code fpocket and rank them on the basis of druggability score. We have identified in a total of 433 pockets on the SARS-CoV-2 proteome and characterized by physicochemical descriptors. In which, 47 pockets identified as druggable and 71 as potential drug-binding pockets.

Keywords

SARS-CoV-2 Pocketome
drug re-purposing
Target-based drug discovery
Virtual screening
PocketStructure

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.